The Dresden Nephrology unit is amongst the leading renal clinical research centers in Europe. We actively initiate or participate in a large number of international multi-center, prospective and randomized, controlled clinical studies. In the following, some of the currently enrolling studies are listed:
| Name der Studie | Studienbeschreibung | Studienlaufzeit |
| PASS (156-12-299) |
6-year, multicentre, non-interventional, post-authorisation safety study (PASS) for patients prescribed JINARC® for Autosomal Dominant Polycystic Kidney Disease |
since 06/2017 |
| REGENCY (CA41705) | Phase III, randomised, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of Obinutuzumab in patients with ISN/RPS 2003 Class III or IV Lupus Nephritis | since 10/2020 |
| CLNP023A2301 | Phase III, multicenter, randomised, double-blind, placebo-controlled parallel dose group study to investigate efficacy and safety of LNP023 in patients with primary IgA nephropathy | since 03/2021 |
| CLNP023D12201 | Open, randomized, two-arm feasibility study with parallel dose groups to investigate efficacy and safety of LNP023 compared to Rituximab in patients with idiopathic membranous nephropathy | since 07/2021 |
| C0221002 | Phase II, 12-week, adaptive, open, sequential cohort study to investigate efficacy, safety, tolerability and pharmacokinetis of PF-06730512 after multiple doses in adult patients with focal segmental glomerulosclerosis (FSGS) | since 07/2021 |
| ORIGIN | Phase IIb, randomised, double-blind, placebo-controlled dose-finding study to investigate efficacy and safety of Atacicept in patients with IgA nephropathy (IgAN) |
since 02/2022 |
| 1378-0005 |
Randomised, double-blind, placebo-controlled and parallel dose group trial to investigate efficacy and safety of multiple doses of oral BI 690517 over 14 weeks, alone and in combination with empagliflozin, in patients with diabetic and non-diabetic chronic kidney disease |
initiation upcoming |
|
|
||
| TTV |
Randomised and controlled trial to compare the safety, tolerability and preliminary efficacy between standard and torque teno-virus-guided immunosuppression in stable adult kidney transplant recipients with low immunological risk in the first year after transplantation - TTV GUIDE TX |
initiation upcoming |
Study nurse team: 
Frau Annegret Fleischer (Tel. 0351-458 18825)
Frau Kerstin Haaser (Tel. 0351-458 19504)
Kooperationspartner: